Paris, France
Paris, France

Time filter

Source Type

Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-11-2015 | Award Amount: 7.42M | Year: 2016

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastatic potential could be gauged by measuring the forces exert by tumours. Furthermore, many solid tumours show a significantly increased interstitial fluid pressure (IFP) which prevents the efficient uptake of therapeutic agents. As a result, a reduction in IFP is recognized as a hallmark of therapeutic efficacy. Currently, there is no non-invasive modality that can directly image these forces in vivo. Our objective is the non-invasive measurement of both IFP within tumours as well as the forces they exert on their surrounding environment. This will be used to predict a tumours metastatic potential and importantly, changes in these forces will be used to predict the therapeutic efficacy of drug therapy. To attain this goal, the biomechanical properties of the tumour and its neighbouring tissue will be measured via MR-elastography at various measured deformation states. Resultant images will be used to reconstruct images of the internal and external forces acting on the tumour. We call this novel imaging modality Magnetic Resonance Force (MRF) imaging. We will calibrate MRF via cell cultures and pre-clinical models, and then test the method in breast, liver, and brain cancer patients. Thereby, we will investigate whether MRF data can predict metastatic spread and measure IFP in patients. We will also investigate the potential to non-invasively modulate the force environment of cancer cells via externally applied shear forces with the aim of impacting cell motility and proliferation. This can provide novel mechanism for anticancer therapeutic agents via mechanotransduction.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-01-2016-2017 | Award Amount: 3.99M | Year: 2017

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimers disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure. Research in the field has long been refining classic concepts based on the aggregation of A and tau through initial seeding and then spreading. Our vision is different and based on the demonstration that tau abnormal phosphorylation and aggregation is triggered by the interaction of tau with heparan sulfates internalized in neurons and circulating cells only in AD [UPEC R.1; P.1,2]. Based in this new concept, ArrestAD will establish links between AD genetics, disease hallmarks, and altered traffic and intracellular accumulation of heparan sulfates to generate new knowledge underpinning the development of new strategies for detection and treatment of AD. This will open to radically new technologies addressing two major objectives: 1) proving that specific and early diagnosis of AD is possible in circulating cells, and 2) demonstrating that a new class of drug candidates are able to preventing and/or arresting AD-neurodegeneration. To reach these objectives, ArrestAD brings together internationally recognized experts in AD clinics and diagnosis, in heparan sulfate biology, transcriptomics, interactomics, carbohydrate chemistry, enzymology, cell biology, animal experimentation with AD models, and a SME specialized in the development of diagnosis kits using circulating cells. The high-risk character of this joint science and technology research is offset by the multidisciplinary nature of the Consortium and the high socio-economic gain resulting from success. Based in this technology, we will build a diverse portfolio of future projects that will result in a long-term benefit for citizens, economy and society.


Wiseguyreports.Com Adds “Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into CellSearch Others Type III Split by applications, this report focuses on sales, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in each application, can be divided into Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Report 2016 1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Overview 1.1 Product Overview and Scope of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2 Classification of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2.1 CellSearch 1.2.2 Others 1.2.3 Type III 1.3 Application of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.3.1 Breast Cancer Diagnosis and Treatment 1.3.2 Prostate Cancer Diagnosis and Treatment 1.3.3 Colorectal Cancer Diagnosis and Treatment 1.3.4 Lung Cancer Diagnosis and Treatment 1.3.5 Other Cancers Diagnosis and Treatment 1.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (2011-2021) 1.5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Growth Rate (2011-2021) 1.5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) 7 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturers Analysis 7.1 Janssen 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Qiagen 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 124 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 Advanced Cell Diagnostics 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 145 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 ApoCell 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Biofluidica 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Clearbridge Biomedics 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 CytoTrack 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Chemical & Material Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 Celsee 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Fluxion 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Gilupi 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 Cynvenio 7.12 On-chip 7.13 YZY Bio 7.14 BioView 7.15 Creatv MicroTech 7.16 Fluidigm 7.17 Ikonisys 7.18 AdnaGen 7.19 IVDiagnostics 7.20 Miltenyi Biotec 7.21 Aviva Biosciences Corporation 7.22 ScreenCell 7.23 Silicon Biosystems 7.24 Global Other


Notes: Sales, means the sales volume of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue, means the sales value of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) This report studies sales (consumption) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Janssen Qiagen Advanced Cell Diagnostics ApoCell Biofluidica Clearbridge Biomedics CytoTrack Celsee Fluxion Gilupi Cynvenio On-chip YZY Bio BioView Creatv MicroTech Fluidigm Ikonisys AdnaGen IVDiagnostics Miltenyi Biotec Aviva Biosciences Corporation ScreenCell Silicon Biosystems Global Other Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into CellSearch Others Type III Split by applications, this report focuses on sales, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in each application, can be divided into Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Report 2016 1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Overview 1.1 Product Overview and Scope of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2 Classification of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2.1 CellSearch 1.2.2 Others 1.2.3 Type III 1.3 Application of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.3.1 Breast Cancer Diagnosis and Treatment 1.3.2 Prostate Cancer Diagnosis and Treatment 1.3.3 Colorectal Cancer Diagnosis and Treatment 1.3.4 Lung Cancer Diagnosis and Treatment 1.3.5 Other Cancers Diagnosis and Treatment 1.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (2011-2021) 1.5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Growth Rate (2011-2021) 1.5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) 2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Competition by Manufacturers, Type and Application 2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competition by Manufacturers 2.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Market Share of Key Manufacturers (2011-2016) 2.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Share by Manufacturers (2011-2016) 2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (Volume and Value) by Type 2.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Market Share by Type (2011-2016) 2.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Market Share by Type (2011-2016) 2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (Volume and Value) by Regions 2.3.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Market Share by Regions (2011-2016) 2.3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Market Share by Regions (2011-2016) 2.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (Volume) by Application Figure Picture of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Table Classification of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Figure Global Sales Market Share of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Type in 2015 Figure CellSearch Picture Figure Others Picture Table Applications of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Figure Global Sales Market Share of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Application in 2015 Figure Breast Cancer Diagnosis and Treatment Examples Figure Prostate Cancer Diagnosis and Treatment Examples Figure Colorectal Cancer Diagnosis and Treatment Examples Figure Lung Cancer Diagnosis and Treatment Examples Figure Other Cancers Diagnosis and Treatment Examples Figure United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Growth Rate (2011-2021) Figure Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales of Key Manufacturers (2011-2016) Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Share by Manufacturers (2011-2016) Figure 2015 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Share by Manufacturers Figure 2016 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Share by Manufacturers Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Manufacturers (2011-2016) Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Manufacturers (2011-2016) Table 2015 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Manufacturers FOR ANY QUERY, REACH US @ Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Global Market Research Report 2016


— This report mainly covers Circulating Tumor Cells products, by types (CTC enrichment, CTC detection and CTC analysis), by applications (Prostate Cancer, Breast Cancer, Colorectal Cancer Diagnosis and Treatment and Others). This report focuses on the Circulating Tumor Cells in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. For more information or any query mail at sales@wiseguyreports.com Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America, Middle East and Africa Market Segment by Applications, can be divided into Prostate Cancer Breast Cancer Colorectal Cancer Others There are 13 Chapters to deeply display the global Circulating Tumor Cells market. Chapter 2, to analyze the top manufacturers of Circulating Tumor Cells, with sales, revenue, and price of Circulating Tumor Cells, in 2015 and 2016; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016; Chapter 4, to show the global market by regions, with sales, revenue and market share of Circulating Tumor Cells, for each region, from 2011 to 2016; 2 Manufacturers Profiles 2.1 Janssen 2.1.1 Business Overview 2.1.2 Circulating Tumor Cells Type and Applications 2.1.2.1 Type 1 2.1.2.2 Type 2 2.1.3 Janssen Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.2 Qiagen(Adnagen) 2.2.1 Business Overview 2.2.2 Circulating Tumor Cells Type and Applications 2.2.2.1 Type 1 2.2.2.2 Type 2 2.2.3 Qiagen(Adnagen) Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.3 Acousys Biodevices, Inc 2.3.1 Business Overview 2.3.2 Circulating Tumor Cells Type and Applications 2.3.2.1 Type 1 2.3.2.2 Type 2 2.3.3 Acousys Biodevices, Inc Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.4 ApoCell 2.4.1 Business Overview 2.4.2 Circulating Tumor Cells Type and Applications 2.4.2.1 Type 1 2.4.2.2 Type 2 2.4.3 ApoCell Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.5 Advanced Cell Diagnostics 2.5.1 Business Overview 2.5.2 Circulating Tumor Cells Type and Applications 2.5.2.1 Type 1 2.5.2.2 Type 2 2.5.3 Advanced Cell Diagnostics Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.6 Fluxion Biosciences 2.6.1 Business Overview 2.6.2 Circulating Tumor Cells Type and Applications 2.6.2.1 Type 1 2.6.2.2 Type 2 2.6.3 Fluxion Biosciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.7 Biocept 2.7.1 Business Overview 2.7.2 Circulating Tumor Cells Type and Applications 2.7.2.1 Type 1 2.7.2.2 Type 2 2.7.3 Biocept Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.8 Fluidigm 2.8.1 Business Overview 2.8.2 Circulating Tumor Cells Type and Applications 2.8.2.1 Type 1 2.8.2.2 Type 2 2.8.3 Fluidigm Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.9 Epic Sciences 2.9.1 Business Overview 2.9.2 Circulating Tumor Cells Type and Applications 2.9.2.1 Type 1 2.9.2.2 Type 2 2.9.3 Epic Sciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.10 Clearbridge Biomedics 2.10.1 Business Overview 2.10.2 Circulating Tumor Cells Type and Applications 2.10.2.1 Type 1 2.10.2.2 Type 2 2.10.3 Clearbridge Biomedics Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.11 Cynvenio 2.11.1 Business Overview 2.11.2 Circulating Tumor Cells Type and Applications 2.11.2.1 Type 1 2.11.2.2 Type 2 2.11.3 Cynvenio Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.12 CytoTrack 2.12.1 Business Overview 2.12.2 Circulating Tumor Cells Type and Applications 2.12.2.1 Type 1 2.12.2.2 Type 2 2.12.3 CytoTrack Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.13 ScreenCell 2.13.1 Business Overview 2.13.2 Circulating Tumor Cells Type and Applications 2.13.2.1 Type 1 2.13.2.2 Type 2 2.13.3 ScreenCell Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.14 Creatv Microtech 2.14.1 Business Overview 2.14.2 Circulating Tumor Cells Type and Applications 2.14.2.1 Type 1 2.14.2.2 Type 2 2.14.3 Creatv Microtech Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.15 Aviva Biosciences 2.15.1 Business Overview 2.15.2 Circulating Tumor Cells Type and Applications 2.15.2.1 Type 1 2.15.2.2 Type 2 2.15.3 Aviva Biosciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.16 Greiner Bio-one GmbH 2.16.1 Business Overview 2.16.2 Circulating Tumor Cells Type and Applications 2.16.2.1 Type 1 2.16.2.2 Type 2 2.16.3 Greiner Bio-one GmbH Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.17 Sysmex Corporation 2.17.1 Business Overview 2.17.2 Circulating Tumor Cells Type and Applications 2.17.2.1 Type 1 2.17.2.2 Type 2 2.17.3 Sysmex Corporation Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.18 Ikonisys 2.18.1 Business Overview 2.18.2 Circulating Tumor Cells Type and Applications 2.18.2.1 Type 1 2.18.2.2 Type 2 2.18.3 Ikonisys Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


Desitter I.,ScreenCell | Guerrouahen B.S.,ScreenCell | Benali-Furet N.,ScreenCell | Wechsler J.,ScreenCell | And 8 more authors.
Anticancer Research | Year: 2011

Background: Circulating tumor cells (CTCs) likely derive from clones in the primary tumor, suggesting that they can be used for all biological tests applying to the primary cells. Materials and Methods: The ScreenCell® devices are single-use and low-cost innovative devices that use a filter to isolate and sort tumor cells by size. Results: The ScreenCell® Cyto device is able to isolate rare, fixed, tumor cells, with a high recovery rate. Cells are well preserved morphologically. Immunocytochemistry and FISH assays can be performed directly on the filter. The ScreenCell® CC device allows isolation of live cells able to grow in culture. High quality genetic materials can be obtained directly from tumor cells isolated on the ScreenCell® MB device filter. Conclusion: Due to their reduced size, versatility, and capacity to isolate CTCs within minutes, the ScreenCell® devices may be able to simplify and improve non-invasive access to tumor cells.


Awe J.A.,University of Manitoba | Awe J.A.,Gothenburg University | Awe J.A.,University of Skövde | Xu M.C.,University of Manitoba | And 7 more authors.
Translational Oncology | Year: 2013

Circulating tumor cells (CTCs) have been identified with the potential to serve as suitable biomarkers for tumor stage and progression, but the availability of effective isolation technique(s) coupled with detailed molecular characterization have been the challenges encountered in making CTCs clinically relevant. For the first time, we combined isolation of CTCs using the ScreenCell filtration technique with quantitative analysis of CTC telomeres by TeloView. This resulted in the identification and molecular characterization of different subpopulations of CTCs in the same patient. Threedimensional (3D) telomeric analysis was carried out on isolated CTCs of 19 patients that consisted of four different tumor types, namely, prostate, colon, breast, melanoma, and one lung cancer cell line.With telomeric analysis of the filter-isolated CTCs, the level of chromosomal instability (CIN) of the CTCs can be determined. Our study shows that subpopulations of CTCs can be identified on the basis of their 3D telomeric properties. Copyright © 2013 Neoplasia Press, Inc. All rights reserved.


Trademark
Screencell | Date: 2011-06-10

Pharmaceutical preparations for the detection, diagnostic and treatment of cancer; veterinary preparations for the detection and diagnostic of cancer; sanitary preparations for medical purposes; Dietetic substances adapted for medical use, namely, dietetic foods, dietetic beverages, dietetic sugar, dietetic sugar substitutes; food for babies; plasters for medical and surgical purposes; materials for dressing, namely, bandages and gauze for dressing, burn dressings and self adhesives dressings; material for dental fillings and dental impressions; disinfectants for medical instruments; pesticides; fungicides; herbicides; bath preparations, medicated; sanitary pads, panties or towels; chemical preparations for medical or pharmaceutical purposes, namely, chemical preparations for the isolation of cells, chemical and pharmaceutical preparations for the detection and treatment of cell mutation; medicinal herbs; herbs teas for medicinal purposes; parasiticides; dietetic sugar for medical purposes; alloys of precious metals for dental purposes. Scientific apparatus and instruments, not for medical use, namely, optical mirrors, glass tubes, Erlenmeyer flasks and beakers for scientific purposes, conductivity meters, chromatography columns for use in purification in the laboratory and parts and fittings therefor, spectrometers and parts and fittings therefor, instruments for measuring relative DNA/RNA and protein and parts and fittings therefor, spectrophotometer for measuring relative DNA/RNA and protein, cellular mixed ester membranes for use in the science and research industry, ultra-high vacuum chambers; surveying apparatus and instruments, namely, surveying machines and instruments, surveying compass needles, magnetic compasses; photographic apparatus and instruments, namely, photographic cameras, photographic exposure meters, photographic filters, photographic flash bulbs and flash units, photographic projectors; cinematographic apparatus and instruments, namely, cinematographic cameras, cinematographic film, cinematographic machines and apparatus, sound recording apparatus and instruments; optical apparatus and instruments, namely, optical filters, optical glasses, optical lens sights, optical scanners, optical readers, optical reflectors; weighing equipment, namely, scales and balances; measuring apparatus and instruments, namely, bevels, lasers for measuring purposes, liquid level sensors, gas level sensors, angle finders, measuring buckets, cups, spoons and glassware, measuring rules; checking apparatus and instruments for measuring, testing and checking the temperature, pressure, quantity and concentration of gas and liquids; life-saving apparatus and instruments, namely, positive pressure breathing systems, defibrillators; teaching apparatus and instruments, namely, medical teaching mannequins, video projectors, medical diagnostic simulators for use as teaching aids for detection of cancer; apparatus for recording, transmission or reproduction of sound or images; blank magnetic recording media; blank recordable acoustic or optical discs; blank floppy discs; automatic vending machines and mechanisms for coin-operated apparatus; cash registers, calculating machines, data processing equipment and computers; computer game programs; computer software, recorded for scientific analysis of genetic sequences; computer peripheral devices; batteries, electric; wires, electric; relays, electric; spectacles; optical goods, namely, optical filters, optical lenses, optical glasses, optical reflectors; spectacles cases; diagnostic apparatus for scientific or research use other than for medical use; integrated circuit cards; safety tarpaulins. Surgical apparatus and instruments for medical, dental and veterinary use; medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; dental instruments, namely, picks, burrs, mirrors, oral irrigators, prophy angles, bridges, drills, inlays, onlays, implants, crowns; artificial limbs, eyes and teeth; orthopedic articles, namely, orthopedic belts, orthopedic braces, orthopedic joint implants; suture materials; feeding bottles; feeding bottle teats; clothing especially for operating rooms, namely, surgical scrub suits; massage apparatus; esthetic massage apparatus; artificial limbs; surgical implants comprising artificial materials; surgical drapes; bed pans or basins for medical use, furniture especially made for medical purposes, surgical cutlery. Evaluations, assessments and research in the fields of science and technology provided by engineers; design and development of computer and software; research and development for others in the field of cytology; technical project studies, namely, research and development of new products for others; architecture; design of interior dcor; development, design, installation, maintenance, updating or rental of software; computer programming; consultancy in the field of computer hardware; data conversion of computer programs and data, not physical conversion; conversion of data or documents from physical to electronic media; automotive safety testing and consultation, namely, conducting crash tests and providing advice, information and reports as to the roadworthiness of vehicles; graphic arts designing, styling, namely, industrial design; authentic works of art.


Patent
Screencell and Dana-Farber Cancer Institute | Date: 2012-09-07

Methods and materials for increasing the number of target cells recovered from a fluid sample containing cells are described. The methods include isolating the target cells on a filter and then implanting the filter containing the target cells in an immunodeficient non-human animal, where at least some of the target cells can proliferate.


PubMed | Biomarkers Unit, ScreenCell and Fondazione IRCCS Instituto Nazionale dei Tumori
Type: Journal Article | Journal: The International journal of biological markers | Year: 2015

To compare circulating tumor cell (CTC) detection rates in patients with early (M0) and metastatic (M+) breast cancer using 2 positive-selection methods or size-based unbiased enrichment.Blood collected at baseline and at different times during treatment from M0 patients undergoing neoadjuvant therapy and from M+ women starting a new line of treatment was processed in parallel using AdnaTest EMT-1/ and EMT-2/Stem CellSelect/Detect kits or ScreenCell Cyto devices. CTC positivity was defined according to the suggested cutoffs and cytological parameters, respectively.Higher CTC detection rates were obtained with the AdnaTest approach when using for CTC-enrichment antibodies against ERBB2 and EGFR in addition to MUC1 and the classical epithelial surface marker EPCAM (13% vs. 48%). In M0 patients mainly, CTC positivity rates further increased when EMT- and stemness-related marker expression (PIK3CA, AKT2 and ALDH1) was evaluated in addition to EPCAM, MUC1 and ERBB2. When the physical properties of tumor cells were exploited, CTCs were detected at higher percentages than with positive-selection-based methods, without any difference between clinical stages (78% in M0 vs. 72% in M+ cases at baseline). Circulating tumor microemboli (CTMs) were detected in addition to single CTCs with significantly higher frequency in M0 than M+ samples (78% vs. 27%, p = 0.0002).Different approaches for CTC detection probably identify distinct tumor cell subpopulations, but need technical standardization before their clinical validity and biological specificity may be adequately investigated. The distinct role of CTMs compared with CTCs as prognostic and predictive biomarkers represents a further challenge.

Loading ScreenCell collaborators
Loading ScreenCell collaborators